Evidence map›Paper›PMID 29045644›Full record

GuidelineEuropean heart journal2018

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.

Ulf Landmesser, M John Chapman, Jane K Stock, Pierre Amarenco, Jill J F Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham and 13 more

Registry-linked trialAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04338165 (Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography), which is not on this map. Cited by 66 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04338165 phase2unknown statusstarted 2021, after this paper: background citation

Effect of Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography : a Monocentric, Prospective, Randomized and Open-label Phase II Trial

Ran2021Enrolled66Registered outcomes6Posted comparisons0ConditionsAtherosclerotic Cardiovascular DiseaseArmsEvolocumab 140 MG/ML [Repatha]
PMID 28304224PMID 24625727PMID 29525934PMID 10704159PMID 10779454PMID 11074073PMID 12163423PMID 12821539PMID 15136498PMID 21596324PMID 22176652PMID 22874078other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. The promising novel therapies for familial hypercholesterolemia.Journal of clinical laboratory analysis · 2022
    Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. 2018 Guidelines for the management of dyslipidemia.The Korean journal of internal medicine · 2019
    Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Ulf LandmesserDepartment of Cardiology, Charite Universitätsmedizin Berlin, Berlin Institute of Health (BIH), German Center of Cardiovascular Research (DZHK), Hindenburgdamm 30, 12203 Berlin, Germany.
M John ChapmanNational Institute for Health and Medical Research (INSERM), University of Pierre and Marie Curie, Pitié-Salpêtrière Hospital, Paris, France.
Jane K StockEuropean Atherosclerosis Society, Gothenburg, Sweden.
Pierre AmarencoParis-Diderot-Sorbonne University and Department of Neurology and Stroke Centre, Bichat Hospital, Paris, France.
Jill J F BelchInstitute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee, UK.
Jan BorénDepartment of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, and Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
Michel FarnierLipid Clinic, Point Medical, and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.
Brian A FerenceDivision of Cardiovascular Medicine, Division of Translational Research and Clinical Epidemiology, Wayne State University School of Medicine, Detroit, MI, USA.
Stephan GielenDepartment of Internal Medicine III, Martin-Luther-University Halle/Wittenberg, University Hospital, Halle/Saale, Germany.
Ian GrahamTrinity College, Dublin, Ireland.
Diederick E GrobbeeJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
G Kees HovinghDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Thomas F LüscherUniversity Heart Center, Department of Cardiology, University Hospital Zurich, and Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland.
Massimo F PiepoliHeart Failure Unit, Cardiac Department, G Da Saliceto Hospital, Piacenza, Italy.
Kausik K RayImperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College, London, UK.
Erik S StroesDepartment of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Olov WiklundSahlgrenska University Hospital, Gothenburg, Sweden.
Stephan WindeckerDepartment of Cardiology, Swiss Cardiovascular Center Bern, Bern University Hospital, Bern, Switzerland.
Jose Luis ZamoranoDepartment of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain.
Fausto PintoCardiology Department, CCUL, CAML, Faculdade de Medicina, Universidade de Lisboa, Portugal.
Lale TokgözogluDepartment of Cardiology, Hacettepe University, Ankara, Turkey.
Jeroen J BaxDepartment of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
Alberico L CatapanoDepartment of Pharmacological and Biomolecular Sciences, University of Milan and Multimedica IRCSS Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

PCSK9 InhibitorsAdultAdvisory CommitteesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCoronary Artery DiseaseFemaleHumansHyperlipoproteinemia Type IIMaleMiddle AgedProprotein Convertase 9Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsevolocumabPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID29045644

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.